{"id":52697,"date":"2026-01-04T14:28:19","date_gmt":"2026-01-04T06:28:19","guid":{"rendered":"https:\/\/flcube.com\/?p=52697"},"modified":"2026-01-04T14:28:19","modified_gmt":"2026-01-04T06:28:19","slug":"nhc-releases-fourth-batch-generic-drugs-catalogue-prioritizing-innovation-and-fertility-support","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52697","title":{"rendered":"NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support"},"content":{"rendered":"\n<p>The <strong>National Health Commission (NHC)<\/strong> released the <strong>Fourth Batch of the National Catalogue of Encouraged Generic Drugs<\/strong>, comprising <strong>21 drug varieties and 47 specifications<\/strong>. The catalogue focuses on four strategic priorities: innovative mechanisms, international guideline alignment, pro\u2011fertility formulations, and rare disease access.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-catalogue-summary\">Catalogue Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Issuing Authority<\/strong><\/td><td>National Health Commission (NHC)<\/td><\/tr><tr><td><strong>Catalogue<\/strong><\/td><td>Fourth Batch, National Encouraged Generic Drugs<\/td><\/tr><tr><td><strong>Release Date<\/strong><\/td><td>04\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>21 drug varieties, 47 specifications<\/td><\/tr><tr><td><strong>Strategic Focus<\/strong><\/td><td>Clinical gaps, innovation, fertility support, accessibility<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-four-prioritization-strategies\">Four Prioritization Strategies<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-1-innovative-mechanisms-amp-radiopharmaceuticals\"><strong>1. Innovative Mechanisms &amp; Radiopharmaceuticals<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Difelikefalin<\/strong>: First\u2011in\u2011class kappa opioid receptor agonist for <strong>moderate\u2011to\u2011severe pruritus in hemodialysis patients<\/strong> (significant unmet need in CKD)<\/li>\n\n\n\n<li><strong>Four Radiopharmaceuticals<\/strong>: Covering therapeutic, diagnostic, and localization applications\u2014not yet marketed in China<\/li>\n\n\n\n<li><strong>Market Gap<\/strong>: Addresses domestic R&amp;D weaknesses in novel targets; positions China to capture <strong>\u00a58\u201112 billion radiopharmaceutical market<\/strong> by 2030<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-2-international-guideline-aligned-therapies\"><strong>2. International Guideline\u2011Aligned Therapies<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Suvorexant<\/strong>: Dual orexin receptor antagonist for <strong>insomnia<\/strong>, addressing sleep onset\/maintenance with <strong>reduced daytime sleepiness<\/strong> vs. benzodiazepines<\/li>\n\n\n\n<li><strong>Strategic Value<\/strong>: Supplements limited domestic options; aligns with <strong>WHO and AASM guidelines<\/strong>; estimated <strong>\u00a52\u20113 billion<\/strong> market potential in China<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-3-pro-fertility-formulations\"><strong>3. Pro\u2011Fertility Formulations<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Progesterone Vaginal Sustained\u2011Release Gel\/Suppository<\/strong>: Used in <strong>IVF\u2011ET cycles<\/strong><\/li>\n\n\n\n<li><strong>Advantage<\/strong>: Eliminates injection\u2011site reactions (redness, induration, panniculitis) from oil\u2011based injections; improves patient compliance<\/li>\n\n\n\n<li><strong>Policy Synergy<\/strong>: Directly supports China\u2019s <strong>pro\u2011fertility initiatives<\/strong>; addresses side\u2011effect barriers in <strong>3\u20114 million annual IVF cycles<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-4-rare-disease-accessibility\"><strong>4. Rare Disease Accessibility<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Deflazacort<\/strong>: Glucocorticoid for <strong>Duchenne Muscular Dystrophy (DMD)<\/strong>, a rare pediatric disease<\/li>\n\n\n\n<li><strong>Market Need<\/strong>: Estimated <strong>6,000\u20118,000 DMD patients<\/strong> in China; limited treatment options beyond corticosteroids<\/li>\n\n\n\n<li><strong>Reimbursement Pathway<\/strong>: Catalogue inclusion facilitates <strong>2026\u20112027 NRDL negotiation<\/strong> under rare disease provisions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<p><strong>Innovation Incentive<\/strong>: The catalogue signals <strong>\u00a550\u201180 billion in additional R&amp;D investment<\/strong> over three years, focusing on <strong>oncology, rare diseases, and advanced therapeutics<\/strong>.<\/p>\n\n\n\n<p><strong>Industry Transformation<\/strong>: Accelerates shift from <strong>&#8220;imitation&#8221; to &#8220;innovation&#8221;<\/strong>, strengthening domestic pharmaceutical competitiveness.<\/p>\n\n\n\n<p><strong>Manufacturing Priorities<\/strong>: Companies with capabilities in <strong>complex generics, radiopharmaceuticals, and novel delivery systems<\/strong> (e.g., vaginal sustained\u2011release) will gain procurement advantages.<\/p>\n\n\n\n<p><strong>Patient Access<\/strong>: Shortens time\u2011to\u2011market for high\u2011value generics by <strong>12\u201118 months<\/strong>, improving affordability and clinical options.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><\/p>\n\n\n\n<p>This brief contains forward\u2011looking assessments regarding market size, investment flows, and policy impact resulting from the Fourth Batch catalogue. Actual outcomes may differ due to implementation details, competitive responses, and reimbursement negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Health Commission (NHC) released the Fourth Batch of the National Catalogue of Encouraged&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52698,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[60],"class_list":["post-52697","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-nhc-nhfpc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Health Commission (NHC) released the Fourth Batch of the National Catalogue of Encouraged Generic Drugs, comprising 21 drug varieties and 47 specifications. The catalogue focuses on four strategic priorities: innovative mechanisms, international guideline alignment, pro\u2011fertility formulations, and rare disease access.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52697\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support\" \/>\n<meta property=\"og:description\" content=\"The National Health Commission (NHC) released the Fourth Batch of the National Catalogue of Encouraged Generic Drugs, comprising 21 drug varieties and 47 specifications. The catalogue focuses on four strategic priorities: innovative mechanisms, international guideline alignment, pro\u2011fertility formulations, and rare disease access.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52697\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-04T06:28:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0403.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52697#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52697\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support\",\"datePublished\":\"2026-01-04T06:28:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52697\"},\"wordCount\":384,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52697#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0403.webp\",\"keywords\":[\"NHC (NHFPC)\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52697#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52697\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52697\",\"name\":\"NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52697#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52697#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0403.webp\",\"datePublished\":\"2026-01-04T06:28:19+00:00\",\"description\":\"The National Health Commission (NHC) released the Fourth Batch of the National Catalogue of Encouraged Generic Drugs, comprising 21 drug varieties and 47 specifications. The catalogue focuses on four strategic priorities: innovative mechanisms, international guideline alignment, pro\u2011fertility formulations, and rare disease access.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52697#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52697\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52697#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0403.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0403.webp\",\"width\":1080,\"height\":608,\"caption\":\"NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52697#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support - Insight, China&#039;s Pharmaceutical Industry","description":"The National Health Commission (NHC) released the Fourth Batch of the National Catalogue of Encouraged Generic Drugs, comprising 21 drug varieties and 47 specifications. The catalogue focuses on four strategic priorities: innovative mechanisms, international guideline alignment, pro\u2011fertility formulations, and rare disease access.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52697","og_locale":"en_US","og_type":"article","og_title":"NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support","og_description":"The National Health Commission (NHC) released the Fourth Batch of the National Catalogue of Encouraged Generic Drugs, comprising 21 drug varieties and 47 specifications. The catalogue focuses on four strategic priorities: innovative mechanisms, international guideline alignment, pro\u2011fertility formulations, and rare disease access.","og_url":"https:\/\/flcube.com\/?p=52697","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-04T06:28:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0403.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52697#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52697"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support","datePublished":"2026-01-04T06:28:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52697"},"wordCount":384,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52697#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0403.webp","keywords":["NHC (NHFPC)"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52697#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52697","url":"https:\/\/flcube.com\/?p=52697","name":"NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52697#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52697#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0403.webp","datePublished":"2026-01-04T06:28:19+00:00","description":"The National Health Commission (NHC) released the Fourth Batch of the National Catalogue of Encouraged Generic Drugs, comprising 21 drug varieties and 47 specifications. The catalogue focuses on four strategic priorities: innovative mechanisms, international guideline alignment, pro\u2011fertility formulations, and rare disease access.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52697#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52697"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52697#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0403.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0403.webp","width":1080,"height":608,"caption":"NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52697#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0403.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52697"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52697\/revisions"}],"predecessor-version":[{"id":52699,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52697\/revisions\/52699"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52698"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}